37.77
                                            
            Harrow Inc stock is traded at $37.77, with a volume of 496.79K.
            It is up +0.56% in the last 24 hours and down -21.61% over the past month.
            Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company's FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company's ophthalmology-focused pharmaceutical compounding business.
        
        See More
    Previous Close:
              $37.56
            Open:
              $37.68
            24h Volume:
                496.79K
            Relative Volume:
              0.71
            Market Cap:
                $1.40B
            Revenue:
              $154.15M
            Net Income/Loss:
              $-33.58M
            P/E Ratio:
              -39.34
            EPS:
                -0.96
            Net Cash Flow:
                $-20.74M
            1W Performance:
              -1.95%
            1M Performance:
              -21.61%
            6M Performance:
                +52.48%
            1Y Performance:
              -16.18%
            Harrow Inc Stock (HROW) Company Profile
Name
                  
                      Harrow Inc
                    
                Sector
                  Phone
                  
                      615.733.4731
                    
                Address
                  
                      1A BURTON HILLS BLVD, NASHVILLE, CA
                    
                Compare HROW with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS | 
|---|---|---|---|---|---|---|
|   
                          
                                HROW
                            
                             Harrow Inc | 37.77 | 1.39B | 154.15M | -33.58M | -20.74M | -0.96 | 
|   
                          
                                ZTS
                            
                             Zoetis Inc | 144.09 | 63.86B | 9.39B | 2.62B | 2.22B | 5.8121 | 
|   
                          
                                TAK
                            
                             Takeda Pharmaceutical Co Adr | 13.44 | 41.80B | 29.96B | 957.25M | 4.77B | 0.2956 | 
|   
                          
                                HLN
                            
                             Haleon Plc Adr | 9.27 | 40.88B | 14.26B | 1.98B | 2.47B | 0.4327 | 
|   
                          
                                TEVA
                            
                             Teva Pharmaceutical Industries Ltd Adr | 20.48 | 22.98B | 16.70B | -157.13M | 1.19B | -0.1446 | 
|   
                          
                                UTHR
                            
                             United Therapeutics Corp | 445.43 | 19.53B | 3.08B | 1.24B | 1.07B | 25.61 | 
Harrow Inc Stock (HROW) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change | 
|---|---|---|---|
| Jul-11-25 | Initiated | Cantor Fitzgerald | Overweight | 
| Jun-12-25 | Initiated | BTIG Research | Buy | 
| Jun-10-25 | Initiated | William Blair | Outperform | 
| Feb-06-25 | Initiated | H.C. Wainwright | Buy | 
| Dec-04-24 | Reiterated | B. Riley Securities | Buy | 
| Apr-11-24 | Initiated | Craig Hallum | Buy | 
| Sep-08-22 | Resumed | B. Riley Securities | Buy | 
| Oct-14-21 | Resumed | B. Riley Securities | Buy | 
| Sep-24-21 | Initiated | Aegis Capital | Buy | 
| Jul-02-21 | Initiated | Ladenburg Thalmann | Buy | 
                    View All
                     
                  
                Harrow Inc Stock (HROW) Latest News
Best data tools to analyze Harrow Inc. stockWeekly Trade Analysis & Verified Trade Idea Suggestions - newser.com
Can Harrow Inc. stock sustain market leadershipWeekly Risk Report & AI Forecast for Swing Trade Picks - newser.com
How Harrow Inc. stock reacts to global recession fearsProfit Target & Weekly Market Pulse Alerts - newser.com
Why Harrow Inc. stock is in analyst buy zone2025 Winners & Losers & Risk Managed Investment Strategies - newser.com
What insider trading reveals about Harrow Inc. stock2025 Pullback Review & Fast Entry High Yield Stock Tips - newser.com
What risks investors should watch in Harrow Inc. stockWeekly Trade Analysis & Reliable Entry Point Alerts - newser.com
Will Harrow Inc. stock pay special dividends2025 Bull vs Bear & AI Powered Market Trend Analysis - newser.com
Corrado Advisors LLC Purchases Shares of 7,366 Harrow, Inc. $HROW - MarketBeat
Custom watchlist performance reports with Harrow Inc.Portfolio Profit Report & Low Risk Profit Maximizing Plans - newser.com
What is the fair value of Harrow Inc. stock now2025 Price Targets & Free Verified High Yield Trade Plans - newser.com
Analyzing Harrow Inc. with risk reward ratio chartsPortfolio Profit Report & Trade Opportunity Analysis - newser.com
Key resistance and support levels for Harrow Inc.July 2025 Setups & Verified Swing Trading Watchlists - newser.com
Should you hold or exit Harrow Inc. now2025 Price Action Summary & Consistent Profit Focused Trading Strategies - newser.com
D.A. Davidson & CO. Sells 13,255 Shares of Harrow, Inc. $HROW - MarketBeat
Harrow, Inc. Experiences Revision in Stock Evaluation Amid Mixed Market Indicators - Markets Mojo
Harrow To Report Third Quarter 2025 Financial Results After Market Close on November 10, 2025 - The Manila Times
Harrow (NASDAQ: HROW) sets third-quarter results Nov 10; call and webcast Nov 11 - Stock Titan
Kornitzer Capital Management Inc. KS Acquires New Position in Harrow, Inc. $HROW - MarketBeat
Bleakley Financial Group LLC Makes New Investment in Harrow, Inc. $HROW - MarketBeat
Will Harrow Inc. stock keep outperforming rivalsDollar Strength & Real-Time Market Trend Scan - newser.com
Weiss Ratings Reaffirms "Sell (E+)" Rating for Harrow (NASDAQ:HROW) - MarketBeat
Sundram Fasteners Limited (SUNDRMFAST) to Launch New Product LineChart Pattern Recognition & Double Or Triple Investment - earlytimes.in
Harrow Inc Stock (HROW) Financials Data
Revenue
Net Income
Cash Flow
EPS
Harrow Inc Stock (HROW) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | 
|---|---|---|---|---|---|---|---|
| Opaleye Management Inc. | 10% Owner | Jun 10 '25 | Sale | 30.80 | 15,000 | 462,033 | 90,000 | 
| Opaleye Management Inc. | 10% Owner | Jun 09 '25 | Sale | 30.37 | 15,204 | 461,794 | 105,000 | 
| Opaleye Management Inc. | 10% Owner | Jun 03 '25 | Sale | 30.04 | 3,000 | 90,116 | 122,000 | 
| Opaleye Management Inc. | 10% Owner | Jun 04 '25 | Sale | 30.02 | 1,796 | 53,907 | 120,204 | 
| Opaleye Management Inc. | 10% Owner | May 12 '25 | Sale | 25.90 | 10,000 | 258,959 | 130,000 | 
| Opaleye Management Inc. | 10% Owner | May 13 '25 | Sale | 26.59 | 5,000 | 132,945 | 125,000 | 
| BOLL ANDREW R. | Chief Financial Officer | Apr 03 '25 | Option Exercise | 0.00 | 346,500 | 0 | 914,589 | 
| SAHAREK JOHN P. | CEO & President, ImprimisRx | Apr 03 '25 | Option Exercise | 0.00 | 277,200 | 0 | 576,863 | 
| BAUM MARK L | Chief Executive Officer | Apr 03 '25 | Option Exercise | 0.00 | 762,300 | 0 | 2,899,825 | 
| Opaleye Management Inc. | 10% Owner | Mar 18 '25 | Sale | 30.01 | 5,000 | 150,055 | 140,000 | 
        Open in Yahoo
        |
        Open in Google
            |
            Open in Finviz
        |
        Open in MarketWatch
            |
            Open in EDGAR    
        |
        Open in Reuters
    
    
                Cap:
                 
                  | 
                Volume (24h):
                 
            
         
                     
                             Get the Stockscreener App
                    Get the Stockscreener App